GRANIX
Peaktbo-filgrastim
BLAINJECTIONINJECTABLE
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
GRANIX (tbo-filgrastim) is tbo-filgrastim is a human granulocyte colony-stimulating factor (g-csf) produced by recombinant dna technology. First approved in 2012.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GRANIX (tbo-filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) approved in 2012 for managing neutropenia in patients with breast cancer, lung cancer, and other conditions. The drug binds to G-CSF receptors to stimulate neutrophil proliferation and differentiation, restoring immune function in patients experiencing chemotherapy-induced neutropenia.
$2MPart D
PeakGRANIX remains in peak commercial phase with modest Part D spending ($2M in 2023), indicating a niche supportive care role with limited commercial expansion potential.
Mechanism of Action
Tbo-filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates proliferation of neutrophils. G-CSF is known to stimulate differentiation commitment and some end-cell functional activation, which…
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Started May 2015
50 enrolled
Neutropenia
Career Relevance
GRANIX shows zero linked job postings and minimal commercial momentum ($2M Part D spend, 30% competitive pressure), indicating limited career expansion on this brand. Roles available would center on mature product management, reimbursement, and defensive positioning against biosimilar competition.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.